BiotechTube
A3P Biomedical

A3P Biomedical

Uppsala, Sweden· Est.
a3p.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

A3P Biomedical is a private, commercial-stage diagnostics company with a validated product, Stockholm3, for prostate cancer risk stratification. The test has demonstrated superior performance compared to the standard PSA test, finding more aggressive cancers while reducing over-diagnosis, as shown in studies involving over 90,000 men. With recent leadership appointments and inclusion in major clinical guidelines, the company is positioned for growth in the global prostate cancer screening market. Its business model is centered on the commercialization of its diagnostic test.

OncologyUrology

Technology Platform

Multi-parametric blood test combining protein biomarkers, genetic biomarkers (SNPs), and clinical variables through a proprietary algorithm for prostate cancer risk stratification.

Opportunities

The massive, global prostate cancer screening market is ripe for disruption due to the well-documented limitations of the PSA test.
Inclusion in the NCCN guidelines provides a powerful catalyst for adoption in the US and other markets that follow these standards.
The company's strong clinical evidence base positions it favorably for reimbursement discussions and potential partnerships with larger diagnostic distributors.

Risk Factors

The primary risk is commercial execution, including achieving widespread reimbursement for a higher-cost test in cost-conscious healthcare systems.
The company faces competition from both the entrenched PSA standard and new liquid biopsy platforms.
As a private, relatively small company, scaling global commercial operations presents significant execution and financial challenges.

Competitive Landscape

A3P competes directly with the standard PSA test and other reflex tests like the Prostate Health Index (PHI) and 4Kscore. It also exists in a broader competitive landscape that includes emerging multi-cancer early detection (MCED) liquid biopsy tests from companies like Grail and Exact Sciences. A3P's differentiation is its deep, population-based clinical validation specifically for prostate cancer and its demonstrated ability to improve clinical outcomes while reducing costs.

More companies in Diagnostics & Precision Medicine →More companies in Sweden →